Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2008

01-02-2008

Clinical and economic benefits of an anticoagulation management service (AMS) for cardiac surgery patients

Authors: Paula J. Biscup-Horn, Michael B. Streiff, Timothy R. Ulbrich, Todd W. Nesbit, Kenneth M. Shermock

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2008

Login to get access

Excerpt

Management of anticoagulation in hospitalized patients with multiple medications and co-morbid conditions can be challenging, particularly after major surgery. Previous studies have demonstrated the value of specialized anticoagulation management services, especially in the outpatient setting. The purpose of our retrospective study was to determine the clinical and economic benefits of an inpatient anticoagulation management service (AMS) in post-operative cardiac surgery patients. Using administrative and clinical databases, we assessed the impact of specialized anticoagulation management on clinical and economic measures in consecutive cardiac surgery patients hospitalized before (1/1/03–5/30/05) and after (6/1/05–12/31/05) provision of specialized AMS on the cardiac surgery service. Outcome measures were the number of INR values >5, the number of clinically significant episodes of bleeding or thromboembolism (venous thromboembolism or cerebrovascular accident), the post-surgical length of stay (LOS) and the total attributable costs of hospitalization and re-operation for bleeding. Comparisons between the study groups (before and after the AMS) were conducted using a chi-square or Fisher’s exact test for categorical measures and a student’s t-test or Wilcoxon rank sum test for continuous outcome measures. For all tests of statistical significance, P-values <0.05 were considered statistically significant. Analyses were performed using STATA, version 9.0 (Stata Corp., College Station, TX). Eight hundred twenty seven patients were admitted during the study period, 674 patients before and 153 patients after institution of the AMS. AMS care was associated with a decrease in the percent of patients with INR values >5 (13% vs. 7%, P = 0.036) and a trend toward fewer bleeding episodes requiring a return visit to the operating room (8 vs. 0, P > 0.05). No difference in post-operative thromboembolic events (8% vs. 11%, P > 0.05) was noted. Post-operative LOS declined from 13.9 days to 11.6 days after initiation of the AMS (P = 0.015). The annual attributable cost savings of AMS care was estimated to be $280,000. Our study demonstrates that a specialized inpatient AMS is associated with improved clinical and economic outcomes for cardiac surgery patients. …
Metadata
Title
Clinical and economic benefits of an anticoagulation management service (AMS) for cardiac surgery patients
Authors
Paula J. Biscup-Horn
Michael B. Streiff
Timothy R. Ulbrich
Todd W. Nesbit
Kenneth M. Shermock
Publication date
01-02-2008
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0114-9

Other articles of this Issue 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.